<DOC>
	<DOCNO>NCT01407575</DOCNO>
	<brief_summary>The purpose study compare safety efficacy buprenorphine placebo adult treatment resistant depression ( TRD ) .</brief_summary>
	<brief_title>Buprenorphine Treatment Resistant Depression</brief_title>
	<detailed_description>Rates treatment resistant depression ( TRD ) randomize control trial range 50-80 % use SSRIs SNRIs . Innovative treatment sorely need . Modulation opiate system may novel treatment approach TRD . Buprenorphine ( BUP ) partial agonist mu-receptors , also display affinity kappa delta receptor . BUP favorable safety profile low risk respiratory depression , pharmacokinetics affect advanced age renal dysfunction . This combination mu-agonism kappa-antagonism produce less dysphoria methadone , animal study suggest kappa-antagonism may exert antidepressant effect . In small proof concept RCT ( n=20 ) , investigator hypothesize difference group receive buprenorphine group receive placebo follow : 1 ) depression , anxiety , sleep , 2 ) activation limbic system brain structure rich opiate receptor critical reward circuit . In addition , investigator hypothesize difference measure safety ( vital sign , measure memory reaction time , fall ) two group . This pilot project provide compel preliminary data support R01 application test efficacy buprenorphine therapeutically challenging patient . Specific Aims : 1 . Describe relative safety BUP adult TRD . The investigator hypothesize difference vital sign , measure memory reaction time , fall two group . 2 . Describe clinical effect BUP adult TRD . The investigator hypothesize depression , anxiety , sleep , health-related quality life , improve great extent among receive BUP . 3 . Characterize change phMRI response buprenorphine compare placebo . The investigator compare activation limbic system ( rACC , insula , amygdala ) brain structure rich opiate receptor ( periaqueductal grey ) critical reward circuit ( nucleus accumbens ) immediately administration BUP placebo . The investigator recruit 20 community-dwelling adult , age 21 old , try least two FDA-approved antidepressant medication therapeutic dos least 6 week episode depression , still depress .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Age 21 old Major depressive disorder Nonresponder least 2 FDAapproved antidepressant prescribe therapeutic dose , least 6 week , depression nonresponder ongoing study latelife depression research clinic . For woman childbearing age , must negative pregnancy test agree get pregnant participating . Concomitant use strong moderate CYP3A4 inhibitor . Refusal stop opioids . Refusal discontinue alcohol . Refusal discontinue benzodiazepine equivalent lorazepam 2 mg/day prescribe stable dose least past 2 week . Hepatic impairment ( AST/ALT &gt; 1.5 time upper normal ) . Lung disease require supplemental oxygen ( CPAP sleep apnea acceptable ) . Estimated creatinine clearance &lt; 30 mL/min . Inability provide inform consent . Depressive symptom severe enough ( i.e. , MADRS &lt; 10 ) baseline assessment . Dementia , define MMSE &lt; 24 clinical evidence dementia Lifetime diagnosis bipolar I II disorder , schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , current psychotic symptom . Abuse dependence alcohol substance within past 3 month . Meets criteria history abuse dependence upon opioids . High risk suicide . Contraindication buprenorphine . Inability communicate English . Noncorrectable clinically significant sensory impairment . Unstable medical illness . Subjects take psychotropic medication safely taper discontinue prior study initiation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Receptors , opioid</keyword>
	<keyword>Receptors , opioid , kappa</keyword>
</DOC>